Johnson & Johnson has released details about a one-shot COVID-19 vaccine that is 66% effective overall against the virus.
The announcement comes after a Phase 3 trial of the company's coronavirus vaccine. The efficacy of this dose is higher when it comes to preventing the most serious of symptoms.
"And that's really important here," says KYW Medical Editor Dr. Brian McDonough.
"It's 85% effective against something that would send you home from work, let's say, and it appears to be 100% effective against ending up in the ICU and being one of those very sick patients," he said.
This is good news for an overwhelmed health care system.
Both the Pfizer and Moderna vaccines in use in the United States show 94% to 95% efficacym, but the FDA over the summer said a baseline of 50% would really make an impact in this pandemic.
It is also important to note that Johnson & Johnson's vaccine comes in a single-dose. The others require two doses to be effective. This means that if this new vaccine gets FDA approval for emergency use, it will certainly help to alleviate vaccine supply issues.
Additionally, the Johnson & Johnson shot doesn't require the deep freeze that the Pfizer vaccine does. This could hopefully alleviate some of the logistical difficulties of transporting and storing the vaccine.
The company says it will apply for that emergency use authorization soon and could get 100 million doses to the U.S. by June.